Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the sale, the director now directly owns 1,500 shares of the company’s stock, valued at $570,735. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ REGN opened at $376.33 on Friday. The stock has a market cap of $41.08 billion, a P/E ratio of 23.10, a PEG ratio of 1.27 and a beta of 1.26. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $505.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.60 by $0.85. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $4.17 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals Inc will post 19.4 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Loomis Sayles & Co. L P grew its position in Regeneron Pharmaceuticals by 34.2% during the first quarter. Loomis Sayles & Co. L P now owns 2,819,755 shares of the biopharmaceutical company’s stock worth $971,011,000 after buying an additional 718,144 shares during the period. Janus Henderson Group PLC grew its position in Regeneron Pharmaceuticals by 12.7% during the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock worth $621,927,000 after buying an additional 203,306 shares during the period. Polen Capital Management LLC grew its position in Regeneron Pharmaceuticals by 4.5% during the second quarter. Polen Capital Management LLC now owns 1,483,634 shares of the biopharmaceutical company’s stock worth $511,839,000 after buying an additional 64,493 shares during the period. Sustainable Growth Advisers LP grew its position in Regeneron Pharmaceuticals by 18.6% during the first quarter. Sustainable Growth Advisers LP now owns 1,045,910 shares of the biopharmaceutical company’s stock worth $360,169,000 after buying an additional 163,981 shares during the period. Finally, American Century Companies Inc. grew its position in Regeneron Pharmaceuticals by 9.1% during the first quarter. American Century Companies Inc. now owns 957,189 shares of the biopharmaceutical company’s stock worth $329,618,000 after buying an additional 79,602 shares during the period. 65.76% of the stock is owned by hedge funds and other institutional investors.

REGN has been the subject of a number of research reports. Canaccord Genuity reaffirmed a “$367.74” rating and issued a $304.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, July 19th. TheStreet raised shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, July 25th. Credit Suisse Group set a $420.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 5th. Leerink Swann set a $435.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 4th. Finally, BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $418.04.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Market Capitalization and Individual Investors

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.